期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Liposomes as versatile agents for the management of traumatic and nontraumatic central nervous system disorders:drug stability,targeting efficiency,and safety
1
作者 Mingyu Zhang Chunyu Xiang +4 位作者 Renrui Niu Xiaodong He Wenqi Luo Wanguo Liu Rui Gu 《Neural Regeneration Research》 SCIE CAS 2025年第7期1883-1899,共17页
Various nanoparticle-based drug delivery systems for the treatment of neurological disorders have been widely studied.However,their inability to cross the blood–brain barrier hampers the clinical translation of these... Various nanoparticle-based drug delivery systems for the treatment of neurological disorders have been widely studied.However,their inability to cross the blood–brain barrier hampers the clinical translation of these therapeutic strategies.Liposomes are nanoparticles composed of lipid bilayers,which can effectively encapsulate drugs and improve drug delivery across the blood–brain barrier and into brain tissue through their targeting and permeability.Therefore,they can potentially treat traumatic and nontraumatic central nervous system diseases.In this review,we outlined the common properties and preparation methods of liposomes,including thin-film hydration,reverse-phase evaporation,solvent injection techniques,detergent removal methods,and microfluidics techniques.Afterwards,we comprehensively discussed the current applications of liposomes in central nervous system diseases,such as Alzheimer's disease,Parkinson's disease,Huntington's disease,amyotrophic lateral sclerosis,traumatic brain injury,spinal cord injury,and brain tumors.Most studies related to liposomes are still in the laboratory stage and have not yet entered clinical trials.Additionally,their application as drug delivery systems in clinical practice faces challenges such as drug stability,targeting efficiency,and safety.Therefore,we proposed development strategies related to liposomes to further promote their development in neurological disease research. 展开更多
关键词 Alzheimer's disease amyotrophic lateral sclerosis brain tumors central nervous system Huntington's disease liposome drug delivery neurological disorders Parkinson's disease spinal cord injury traumatic brain injury
下载PDF
Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases 被引量:2
2
作者 Fatemeh Zahedipour Seyede Atefe Hosseini +2 位作者 Neil C.Henney George E.Barreto Amirhossein Sahebkar 《Neural Regeneration Research》 SCIE CAS CSCD 2022年第8期1675-1684,共10页
Inflammatory processes and proinflammatory cytokines have a key role in the cellular processes of neurodegenerative diseases and are linked to the pathogenesis of functional and mental health disorders.Tumor necrosis ... Inflammatory processes and proinflammatory cytokines have a key role in the cellular processes of neurodegenerative diseases and are linked to the pathogenesis of functional and mental health disorders.Tumor necrosis factor alpha has been reported to play a major role in the central nervous system in Alzheimer’s disease,Parkinson’s disease and amyotrophic lateral sclerosis and many other neurodegenerative diseases.Therefore,a potent proinflammatory/proapoptotic tumor necrosis factor alpha could be a strong candidate for targeted therapy.Plant derivatives have now become promising candidates as therapeutic agents because of their antioxidant and chemical characteristics,and anti-inflammatory features.Recently,phytochemicals including flavonoids,terpenoids,alkaloids,and lignans have generated interest as tumor necrosis factor alpha inhibitor candidates for a number of diseases involving inflammation within the nervous system.In this review,we discuss how phytochemicals as tumor necrosis factor alpha inhibitors are a therapeutic strategy targeting neurodegeneration. 展开更多
关键词 brain central nervous system CYTOKINE herbal medicine INFLAMMATION neurodegenerative diseases PHYTOCHEMICALS tumor necrosis factor-alpha
下载PDF
Interdisciplinary management of central nervous system metastasis and neoplastic meningitis:recent developments and future perspectives
3
作者 Ghazaleh Tabatabai Marilin Koch +27 位作者 Cristiana Roggia Juliane Ebert Claus Garbe Friedegund Meier Sara Brucker Eva Maria Grischke Diethelm Wallwiener Robert Möhle Lothar Kanz Walter Erich Aulitzky Ulrike Ernemann Christian laFougere Konstantin Nikolaou Bernd Pichler Jens Schittenhelm Manuela Neumann Falko Fend Stefan Czemmel Sven Nahnsen Frank Paulsen Daniel Zips Maike van Lessen Hans-Otto Karnath Ulf Ziemann Constantin Roder Marco Skardelly Jürgen Bernd Honegger Marcos Tatagiba 《Journal of Cancer Metastasis and Treatment》 CAS 2016年第1期163-175,共13页
The incidence of metastatic disease in the central nervous system(CNS)is rising.According to current estimates,up to a third of adult cancer patients will suffer from CNS metastasis.Clinical evidence-based data from p... The incidence of metastatic disease in the central nervous system(CNS)is rising.According to current estimates,up to a third of adult cancer patients will suffer from CNS metastasis.Clinical evidence-based data from prospective randomized trials are rare,however,because CNS metastasis patients were often excluded from clinical trial participation.The management of CNS metastasis patients is therefore rather ill-defined and an interdisciplinary challenge.Recent basic and translational science data have begun contributing to a more profound understanding of the molecular mechanisms leading to invasion of tumor cells into the CNS.This report reviews advances,challenges,and perspectives in this field. 展开更多
关键词 brain tumor central nervous system metastases interdisciplinary management
原文传递
Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases
4
作者 Hanfei Guo Bin Wang +2 位作者 Wenqian Li Naifei Chen Jiuwei Cui 《Holistic Integrative Oncology》 2023年第1期300-317,共18页
Brain metastases are the most common central nervous system malignancies in adults.The popular view is that due to the existence of the blood–brain barrier,whether there are immune cells in the central nervous system... Brain metastases are the most common central nervous system malignancies in adults.The popular view is that due to the existence of the blood–brain barrier,whether there are immune cells in the central nervous system has always been controversial.Current research shows that immune cells do exist in the central nervous system and play a vital role in the occurrence and development of brain metastasis.The central nervous system has a unique immune microenvironment,and the study of its mechanism is of great significance for the prediction and treatment of brain metastases.This article aims to discuss the components of the brain tumor microenvironment(TME)and immune mechanism of tumor brain metastasis,in the hopes of making better treatment through combination therapy. 展开更多
关键词 IMMUNOTHERAPY central nervous system brain metastases Tumor microenvironment
原文传递
经不同静脉输液装置给予颅内恶性肿瘤患儿大剂量甲氨蝶呤的安全性比较 被引量:2
5
作者 续茜桥 时正媛 +1 位作者 杨春静 王淑梅 《中国药房》 CAS 北大核心 2023年第7期844-848,共5页
目的比较颅内恶性肿瘤患儿经外周穿刺中心静脉导管(PICC)与植入式静脉输液港(TIVAP)给予大剂量甲氨蝶呤(HD-MTX)的安全性。方法回顾性分析本院2018年7月至2022年4月经PICC或TIVAP给予HD-MTX的颅内恶性肿瘤患儿病例,收集临床资料,比较两... 目的比较颅内恶性肿瘤患儿经外周穿刺中心静脉导管(PICC)与植入式静脉输液港(TIVAP)给予大剂量甲氨蝶呤(HD-MTX)的安全性。方法回顾性分析本院2018年7月至2022年4月经PICC或TIVAP给予HD-MTX的颅内恶性肿瘤患儿病例,收集临床资料,比较两组患儿甲氨蝶呤(MTX)血药浓度、不良事件(包括药物不良反应和导管相关并发症)发生率及住院天数差异。应用多因素线性回归分析MTX血药浓度的影响因素。结果共纳入病例107例,其中PICC组65例、TIVAP组42例。TIVAP组给药后24 h MTX血药浓度(C24 h水平)显著高于PICC组[(126.87±61.99)μmol/L vs.(102.45±48.77)μmol/L,P<0.05],给药后42 h MTX血药浓度(C42 h水平)与PICC组比较差异无统计学意义(P>0.05)。多因素线性回归分析结果显示,经TIVAP给药与MTXC24 h水平升高有关(P<0.05)。两组间不良事件发生率与住院天数的差异均无统计学意义(P>0.05)。结论经TIVAP给药可能出现MTX C24 h水平升高,但不会提高不良事件发生率。在实施治疗药物监测的情况下,经TIVAP给予HD-MTX是较为安全的选择。 展开更多
关键词 甲氨蝶呤 植入式静脉输液港 外周穿刺中心静脉导管 颅内恶性肿瘤 治疗药物监测 血药浓度 不良事件
下载PDF
2019年甘肃省肿瘤登记地区脑及中枢神经系统恶性肿瘤流行特征及2010—2019年变化趋势分析
6
作者 张庆 李露 +1 位作者 杨婧 刘玉琴 《中国肿瘤》 CAS CSCD 北大核心 2024年第2期111-117,共7页
[目的]分析2019年甘肃省肿瘤登记地区脑及中枢神经系统恶性肿瘤发病与死亡现状及2010—2019年变化趋势。[方法]根据甘肃省肿瘤登记地区上报的2010—2019年脑及中枢神经系统恶性肿瘤数据,计算发病(死亡)例数、粗发病率(死亡率)、年龄别... [目的]分析2019年甘肃省肿瘤登记地区脑及中枢神经系统恶性肿瘤发病与死亡现状及2010—2019年变化趋势。[方法]根据甘肃省肿瘤登记地区上报的2010—2019年脑及中枢神经系统恶性肿瘤数据,计算发病(死亡)例数、粗发病率(死亡率)、年龄别发病率(死亡率)、累积率(0~74岁)、截缩率(35~64岁)、标化发病(死亡)率。中国人口标化率(简称为中标率)根据2000年全国普查标准人口的年龄构成计算,世界人口标化率(简称为世标率)根据Segi世界标准人口年龄构成计算。运用Joinpoint软件计算年度变化百分比(APC)与平均年度变化百分比(AAPC)。[结果] 2019年甘肃省肿瘤登记地区脑及中枢神经系统恶性肿瘤新发病例数为778例,其中男性346例,女性432例,发病率为8.39/10万,中标率为6.35/10万,世标率为6.20/10万,0~74岁累积率为0.44%;脑及中枢神经系统恶性肿瘤死亡病例数为332例,其中男性188例,女性144例,死亡率为3.58/10万,中标率为2.60/10万,世标率为2.57/10万,0~74岁累积率为0.15%。农村中标发病率为城市的1.49倍,中标死亡率为城市的1.61倍。脑及中枢神经系统恶性肿瘤年龄别发病率和死亡率都是在75~79岁年龄组达到最高水平,男性发病率最高出现在80~84岁年龄组,而死亡率则是在75~79岁年龄组,女性发病率和死亡率最高分别出现在75~79岁和85岁及以上年龄组。2010—2019年甘肃省肿瘤登记地区脑及中枢神经系统恶性肿瘤中标发病率AAPC为3.21%(95%CI:-0.32%~10.58%),中标死亡率AAPC为-0.05%(95%CI:-1.85%~3.08%)。[结论]甘肃省脑及中枢神经系统恶性肿瘤发病率高于全国平均水平,属于甘肃省重要公共卫生问题,严重影响人们的生活质量,因此应继续加强对脑及中枢神经系统恶性肿瘤的防控,积极推进高危人群筛查工作。 展开更多
关键词 脑及中枢神经系统恶性肿瘤 发病率 死亡率 变化趋势 甘肃
原文传递
安徽省肿瘤登记地区2014年儿童肿瘤发病与死亡情况分析 被引量:14
7
作者 戴丹 李蕊 +2 位作者 查震球 陈叶纪 刘志荣 《中国儿童保健杂志》 CAS 2019年第4期447-450,共4页
目的分析安徽省肿瘤登记地区2014年儿童(0~14岁)肿瘤发病与死亡情况,为制定儿童肿瘤的防治措施提供基础数据。方法对儿童肿瘤资料进行分析,计算肿瘤发病(死亡)率和标化率,并进行城乡和性别之间的比较。结果 2014年安徽省肿瘤登记地区... 目的分析安徽省肿瘤登记地区2014年儿童(0~14岁)肿瘤发病与死亡情况,为制定儿童肿瘤的防治措施提供基础数据。方法对儿童肿瘤资料进行分析,计算肿瘤发病(死亡)率和标化率,并进行城乡和性别之间的比较。结果 2014年安徽省肿瘤登记地区儿童肿瘤粗发病率为9.46/10~5,中标率为8.90/10~5;儿童肿瘤粗死亡率为4.02/10~5,中标率为3.87/10~5。白血病、中枢神经系统肿瘤、骨癌和淋巴瘤为安徽省儿童肿瘤主要发病与死亡癌种。城市儿童肿瘤发病率与死亡率低于农村,男童肿瘤发病率与死亡率高于女童。结论要加强白血病、中枢神经系统肿瘤、骨癌和淋巴瘤重点儿童肿瘤的预防与控制工作,针对儿童肿瘤危险因素采取干预措施,减轻儿童肿瘤发病和死亡带来的严重疾病负担。 展开更多
关键词 白血病 骨癌 中枢神经系统肿瘤 淋巴瘤 儿童
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部